
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Smart Beta ETF report for ...
McKesson (MCK) concluded the recent trading session at $724.11, signifying a -1.53% move from its prior day's close.
Sector ETF report for ...
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Based on the average brokerage recommendation (ABR), McKesson (MCK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
McKesson (MCK) closed at $705.45 in the latest trading session, marking a -3.06% move from the prior day.
These women-run company stocks offer high growth and stability.
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
AEM, NTES, QFIN, UGI and MCK stand out as strong dividend growth picks for steady income and upside in 2H25.
McKesson MCK has outperformed the market over the past 15 years by 4.58% on an annualized basis producing an average annual return of 17.22%. Currently, McKesson has a market capitalization of $90.92 billion.
West Pharmaceutical Services rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
MCK, LRCX, CTSH, and RITM stand out with strong shareholder yield, blending income, buybacks and debt reduction for portfolio defense.
Here is how McKesson (MCK) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.
McKesson's MCK short percent of float has risen 5.95% since its last report. The company recently reported that it has 2.23 million shares sold short, which is 1.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.65 days to cover their ...
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
McKesson MCK has outperformed the market over the past 20 years by 6.76% on an annualized basis producing an average annual return of 15.11%. Currently, McKesson has a market capitalization of $91.59 billion.
McKesson (MCK) concluded the recent trading session at $730.80, signifying a +1.82% move from its prior day's close.
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here is how McKesson (MCK) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
McKesson MCK has outperformed the market over the past 15 years by 4.95% on an annualized basis producing an average annual return of 16.79%. Currently, McKesson has a market capitalization of $90.09 billion.
Both McKesson and Cardinal Health dominate drug distribution, but which stock offers better growth and stability in 2025? Here we discuss which company has better long-term potential.
Based on the average brokerage recommendation (ABR), McKesson (MCK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
COO's fiscal second-quarter results are expected to follow seasonal trends, with a lighter start compared to the previous two reported quarters.
McKesson's strong fundamentals are likely to keep it ahead of the competition. Should investors add it to their portfolio now?
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson MCK has outperformed the market over the past 15 years by 4.93% on an annualized basis producing an average annual return of 16.53%. Currently, McKesson has a market capitalization of $86.16 billion.
McKesson's MCK short percent of float has risen 14.47% since its last report. The company recently reported that it has 2.17 million shares sold short, which is 1.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.59 days to cover their ...
Storied healthcare supplies company McKesson ( NYSE: MCK ) was a slight outperformer on the stock exchange Friday, as investors considered its results for its fourth quarter of fiscal 2025. They liked, if not loved, what they saw, sending the shares to a 0.5% gain on that day.
McKesson's fourth-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
McKesson (MCK) delivered earnings and revenue surprises of 3.16% and 3.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Investors with significant funds have taken a bullish position in McKesson MCK, a development that retail traders should be aware of. This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga.
A more conservative goal of $100 monthly dividend income would require owning 423 shares of McKesson. An investor would need to own $1,526,368 worth of McKesson to generate a monthly dividend income of $500. Get prepared for the Fed's next move-live with Matt Maley on Wednesday, May 7 at 6 PM ...
The average brokerage recommendation (ABR) for McKesson (MCK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
McKesson's fourth-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
Besides Wall Street's top -and-bottom-line estimates for McKesson (MCK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Henry Schein (HSIC) delivered earnings and revenue surprises of 3.60% and 1.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson (MCK) closed at $712.79 in the latest trading session, marking a +0.78% move from the prior day.
McKesson (MCK) reachead $699.73 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.
Merit Medical (MMSI) delivered earnings and revenue surprises of 14.67% and 0.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
MCK moves higher through the session after Alert McKesson, Inc. ( MCK ) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.
In the latest trading session, McKesson (MCK) closed at $695.17, marking a +1.86% move from the previous day.